公开(公告)号：US20250129166A1

公开(公告)日：2025-04-24

申请号：US18939765

申请日：2024-11-07

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Robert J. Johnston ,  Arvind Rajpal ,  Paul O. Sheppard ,  Luis Borges ,  Andrew Rankin ,  Keith Sadoon Bahjat ,  Alan J. Korman ,  Xiaodi Deng ,  Lin Hui Su ,  Ginger Rakestraw ,  Jason R. Pinckney ,  David A. Critton ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina G. Deyanova

IPC: C07K16/28 ,  A61K38/16 ,  C07K16/46

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

公开(公告)号：US12110337B2

公开(公告)日：2024-10-08

申请号：US17045143

申请日：2019-04-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Li-Sheng Lu ,  Mark J. Selby ,  Alan J. Korman ,  Shrikant Deshpande ,  Mohan Srinivasan ,  Jun Zhang ,  Haichun Huang ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina Deyanova

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K39/39541 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92

Abstract: This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

公开(公告)号：US11981734B2

公开(公告)日：2024-05-14

申请号：US17668807

申请日：2022-02-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Natalie Bezman ,  Alan J. Korman ,  Shrikant Deshpande ,  Amy D. Jhatakia ,  Richard Y. Huang ,  Guodong Chen ,  Ginger C. Rakestraw ,  Karla Ann Henning ,  Vangipuram S. Rangan ,  Christine Bee ,  Xiang Shao

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K1/22 ,  C12N5/071 ,  C12N15/85 ,  C12P21/00 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K47/6849 ,  A61P35/00 ,  C07K1/22 ,  C12N5/0682 ,  C12N15/85 ,  C12P21/005 ,  G01N33/68 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  C12N2510/02 ,  C12N2800/107

Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

公开(公告)号：US11591392B2

公开(公告)日：2023-02-28

申请号：US16697653

申请日：2019-11-27

Applicant: Bristol-Myers Squibb Company

Inventor： Xiao Min Schebye ,  Mark J. Selby ,  Michelle Minhua Han ,  Christine Bee ,  Andy X. Deng ,  Anan Chuntharapai ,  Brigitte Devaux ,  Huiming Li ,  Paul O. Sheppard ,  Alan J. Korman ,  Daniel F. Ardourel ,  Ekaterina Deyanova ,  Richard Huang ,  Guodong Chen ,  Michelle Kuhne ,  Hong-An Truong

IPC: A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  A61K47/68 ,  G01N33/574 ,  A61K39/00

Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

公开(公告)号：US11084881B2

公开(公告)日：2021-08-10

申请号：US16578987

申请日：2019-09-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Changyu Wang ,  Nils Lonberg ,  Alan J. Korman ,  Mark J. Selby ,  Mohan Srinivasan ,  Karla Henning ,  Michelle Minhua Han ,  Guodong Chen ,  Richard Huang ,  Indrani Chakraborty ,  Haichun Huang ,  Susan Wong ,  Huiming Li

IPC: C12N15/13 ,  C07K16/28 ,  A61K39/395 ,  G01N33/68 ,  G01N33/574 ,  A61K39/00 ,  A61K47/68

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

公开(公告)号：US10533052B2

公开(公告)日：2020-01-14

申请号：US16017489

申请日：2018-06-25

Applicant: Bristol-Myers Squibb Company

Inventor： Xiao Min Schebye ,  Mark J. Selby ,  Michelle Minhua Han ,  Christine Bee ,  Andy X. Deng ,  Anan Chuntharapai ,  Brigitte Devaux ,  Huiming Li ,  Paul O. Sheppard ,  Alan J. Korman ,  Daniel F. Ardourel ,  Ekaterina Deyanova ,  Richard Huang ,  Guodong Chen ,  Michelle Kuhne ,  Hong-An Truong

IPC: C07K16/30 ,  C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  G01N33/574 ,  A61K39/00

Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

公开(公告)号：US20190382491A1

公开(公告)日：2019-12-19

申请号：US16529230

申请日：2019-08-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Maria Jure-Kunkel ,  David M. Berman ,  Alan J. Korman ,  Mark J. Selby ,  Suba Krishnan

IPC: C07K16/28 ,  C07K16/30

Abstract: This disclosure provides a method for treating a subject afflicted with a cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to PD-1; and (b) an antibody or an antigen-binding portion thereof that specifically binds to CD 137.

公开(公告)号：US10465010B2

公开(公告)日：2019-11-05

申请号：US15646558

申请日：2017-07-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Changyu Wang ,  Nils Lonberg ,  Alan J. Korman ,  Mark J. Selby ,  Mohan Srinivasan ,  Karla Henning ,  Michelle Minhua Han ,  Guodong Chen ,  Richard Huang ,  Indrani Chakraborty ,  Haichun Huang ,  Susan Wong ,  Huiming Li

IPC: C07K16/00 ,  C07H21/00 ,  C07K16/28 ,  A61K39/395 ,  G01N33/68 ,  G01N33/574 ,  A61K39/00 ,  A61K47/68

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

公开(公告)号：US10251945B2

公开(公告)日：2019-04-09

申请号：US16198387

申请日：2018-11-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： John J. Engelhardt ,  Mark J. Selby ,  Alan J. Korman ,  Mary Diane Feingersh ,  Brenda L. Stevens

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.

公开(公告)号：US10100129B2

公开(公告)日：2018-10-16

申请号：US15520638

申请日：2015-11-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nils Lonberg ,  Alan J. Korman ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Ming Lei ,  Emanuela Sega ,  Angela Goodenough ,  Maria Jure-Kunkel ,  Guodong Chen ,  John S. Sack ,  Richard Y. Huang ,  Martin J. Corbett ,  Joseph E. Myers, Jr. ,  Liang Schweizer ,  Sandra V. Hatcher ,  Haichun Huang ,  Pingping Zhang

IPC: A61K39/00 ,  C07K16/40 ,  C07K16/28 ,  A61K47/68 ,  C07K16/30 ,  A61K39/395 ,  A61K45/06 ,  G01N33/574

Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.